Vaccines-2013 - OMICS Group

Recommendations

Info

Carina S. Pinheiro et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAVaccination with enzymatically cleaved GPI-anchored proteins from schistosoma mansoniinduces protection against challenge infectionCarina S. Pinheiro 1,2 , Vicente P. Martins 1,2,3 , Barbara C. P. Figueiredo 1,2 , Natan R. G. Assis 1,2 , Suellen B. Morais 1,2 , Marcelo V. Caliari 4 ,Vasco Azevedo 3 , WilliamCastro-Borges 5 , R. AlanWilson 6 and Sergio C. Oliveira 1, 21Departamento de Bioquímica, Imunologia do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil2Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT-DT), Brazil3Departamento de Biologia Geral do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil4Departamento de Patologia Geral do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil5Departamento Ciências Biológicas, Universidade Federal de Ouro Preto, Brazil6Centre for Immunology & Infection, Department of Biology, University of York, UKThe flatworm Schistosoma mansoni is a blood fluke parasite that causes schistosomiasis, a debilitating disease that occursthroughout the developing world. Current schistosomiasis control strategies are mainly based on chemotherapy, but manyresearchers believe that the best long-term strategy to control schistosomiasis is through immunization with an antischistosomiasisvaccine combined with drug treatment. In the search for potential vaccine candidates, numerous tegument antigens have beenassessed. As the major interface between parasite and mammalian host, the tegument plays crucial roles in the establishmentand further course of schistosomiasis. Herein, we evaluated the potential of a GPI fraction, containing representative moleculeslocated on the outer surface of adult worms, as vaccine candidate. Immunization of mice with GPI-anchored proteins induceda mixed Th1/Th2 type of immune response with production of IFN-γ and TNF-α, and low levels of IL-5 into the supernatant ofsplenocyte cultures. The protection engendered by this vaccination protocol was confirmed by 42% reduction in worm burden,45% reduction in eggs per gram of hepatic tissue, 29% reduction in the number of granulomas per area, and 53% reduction inthe granuloma fibrosis. Taken together, the data herein support the potential of surface-exposed GPI-anchored antigens from theS.mansoni tegument as vaccine candidate.carinaspinheiro@yahoo.com.brJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 144
Dhrubajyoti Nag, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAImmunogenicity and protective efficacy of oral heat-killed multi-serotype Shigella (HKMS)vaccine in rabbit modelDhrubajyoti NagNational Institute of Cholera and Enteric Diseases, IndiaBacillary dysentery caused by Shigella species, is a major cause of infant morbidity and mortality in developed as well asin developing countries. Now-a-days, we are approaching towards untreatable Shigellosis due to the global emergence ofmultidrug resistance which is increasing the importance of an anti-dysentery vaccine. Till date no suitable Shigella vaccineis available for public health use. The immune responses against Shigella species are serotype-specific and there are differentserotypes of Shigella species which demands an immunization strategy that will include multiple vaccine strains to provideprotection against multiple serotypes. In our study, we evaluated the protective efficacy and immune response of heat-killedcocktail form (HKMS) of six Shigella strains (S. dysenteriae 1, S. flexneri 2a, S. flexneri 3a, S. flexneri 6, S. boydii and S. sonnei)in rabbit model. Rabbits were immunized with 10 7 heat-killed Shigella strains four times with one week interval on 0, 7 th , 14 th& 21 st day and were challenged on the 28 th day with 10 9 organisms of wild type virulent Shigella strains. Immunized rabbits didnot develop shigellosis compare to the non-immunized rabbits. Serum IgG and IgA titers showed exponential rise during oralimmunization. Antibody in Lymphocyte Supernatant (ALS) assay, Cytokine assay and Immunoblotting against both whole celllysates and lypopolysaccharide have demonstrated a strong protective immune response following the oral immunization ofHKMS; thus justifying the potential of HKMS to become a “non-living” vaccine candidate against shigellosis in our future.BiographyDhrubajyoti Nag has completed his graduation in Microbiology from University of Calcutta in 2009 and completed his post graduation in Biotechnologyfrom Jadavpur University in 2011. Now he is doing his Ph.D. under the guidance of Dr. Hemanta Koley, Scientist C, National Institute of Choleraand Enteric Diseases, India, under a project of Okayama University, Japan, entitled Development and evaluation of a heat killed multi-serotype oralShigella vaccine.nagdhrubajyoti@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 145
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74:
Young Research ForumSession ChairPe
Page 75 and 76:
Humberto Hernandez et al., J Vaccin
Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90:
Obradovic Zarema et al., J Vaccines
Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143: Birhanu Hurisa et al., J Vaccines V
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?